Immucell Corp (ICCC) 4.59 $ICCC
ImmuCell to Announce Third Quarter Fiscal Year 2014 Financial Results
Marketwired - Mon Nov 03, 7:01AM CST
ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, will report financial results for its third quarter fiscal year 2014 after the market closes on Wednesday, November 12, 2014. The Company has scheduled a conference call that same day Wednesday, November 12, 2014, at 4:30 pm EST to review the results.
ICCC: 4.59 (-0.38)
ImmuCell Participating at Multiple Dairy and Beef Industry Events Throughout September 2014
Marketwire - Wed Sep 17, 7:01AM CDT
ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced today that it will be participating in a number of large industry tradeshows throughout the month of September.
ICCC: 4.59 (-0.38)
ImmuCell Announces Financial Results for the Second Quarter of 2014
Marketwire - Tue Aug 12, 7:01AM CDT
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced financial results for its second quarter ended June 30, 2014.
ICCC: 4.59 (-0.38)
ImmuCell Initiates Pivotal Effectiveness Study to Prevent Calf Scours Caused by Rotavirus
Marketwire - Tue Jul 15, 7:02AM CDT
ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced today that it has commenced a pivotal effectiveness study designed to test antibodies derived from colostrum utilizing its proprietary technology against a bovine rotavirus challenge. The enrollment of calves for the pivotal effectiveness study is expected to be complete by the end of 2014, making product approval possible in 2015.
ICCC: 4.59 (-0.38)
ImmuCell Commences Manufacture of Nisin Necessary for Approval of Mast Out(R)
Marketwire - Wed Jul 09, 7:01AM CDT
ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced today that it has completed modifications to its manufacturing facility to produce pharmaceutical-grade Nisin, the active ingredient in its Mast Out(R) product, to address subclinical mastitis in lactating dairy cows.
ICCC: 4.59 (-0.38)
ImmuCell elects Paul R Wainman to board
M2 - Fri Mar 21, 5:53AM CDT
US-based animal health company ImmuCell (NASDAQ:ICCC) revealed on Thursday the addition of Paul R Wainman to its board of directors
ICCC: 4.59 (-0.38)
Paul R. Wainman Joins Board of Directors of ImmuCell Corporation
Marketwire - Thu Mar 20, 7:01AM CDT
ImmuCell Corporation (NASDAQ: ICCC) today announced that Mr. Paul R. Wainman has been appointed to its Board of Directors effective March 31, 2014.
ICCC: 4.59 (-0.38)
ImmuCell Announces Increase in Product Sales and Other Annual Financial Results
Marketwire - Thu Feb 13, 7:00AM CST
ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and twelve-month periods ended December 31, 2013.
ICCC: 4.59 (-0.38)
OTC Daily Alert Stock Watch - ImmuCell Corporation (NASDAQ: ICCC)
WorldStockWire - Wed Sep 11, 9:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ICCC: 4.59 (-0.38)
ImmuCell Corporation achieves 16% rise in product sales, with continued profitability
M2 - Tue Aug 13, 10:21AM CDT
Animal health company ImmuCell Corporation (NASDAQ:ICCC) on Monday reported a net income of USD6,000, or less than USD0.01 per share, for the three-month period ended 30 June 2013.
ICCC: 4.59 (-0.38)
ImmuCell Announces Increase in Product Sales and Continued Profitability
Marketwire - Mon Aug 12, 7:00AM CDT
ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and six-month periods ended June 30, 2013.
ICCC: 4.59 (-0.38)
Nasdaq stocks posting largest volume increases
AP - Thu Jul 18, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
JAKK: 6.51 (-0.03), ICCC: 4.59 (-0.38), ISIG: 2.98 (+0.03), KFFB: 8.13 (unch), CZFC: 12.00 (-0.49), GLDC: 4.40 (-0.01)
ImmuCell Suspends Mast Out(R) Partnering Effort; Pursuit of FDA Product Approval to Continue
Marketwire - Thu Jul 18, 7:01AM CDT
ImmuCell Corporation (NASDAQ: ICCC) today announced that it has suspended its active pursuit of a partner for Mast Out(R), its Nisin-based intramammary mastitis treatment product under development for dairy cows.
ICCC: 4.59 (-0.38)
First Defense(R) Is Now OMRI Listed and May Be Used With Certified Organic Dairy and Beef Cattle
Marketwire - Thu Jul 11, 7:00AM CDT
ImmuCell Corporation (NASDAQ: ICCC) today announced that First Defense(R), a USDA-approved scours preventative for newborn dairy and beef calves, has been reviewed by the Organic Materials Review Institute (OMRI) and has been listed with products eligible for use in certified organic production, subject to approval by USDA accredited certifiers.
ICCC: 4.59 (-0.38)
ImmuCell Announces Product Sales Increases and Other Financial Results
Marketwire - Thu Feb 14, 7:01AM CST
ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and twelve-month periods ended December 31, 2012.
ICCC: 4.59 (-0.38)
ImmuCell to Announce Third Quarter Fiscal Year 2014 Financial Results
Marketwired - Mon Nov 03, 7:01AM CST
ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, will report financial results for its third quarter fiscal year 2014 after the market closes on Wednesday, November 12, 2014. The Company has scheduled a conference call that same day Wednesday, November 12, 2014, at 4:30 pm EST to review the results.
ICCC: 4.59 (-0.38)
ImmuCell Participating at Multiple Dairy and Beef Industry Events Throughout September 2014
Marketwire - Wed Sep 17, 7:01AM CDT
ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced today that it will be participating in a number of large industry tradeshows throughout the month of September.
ICCC: 4.59 (-0.38)
ImmuCell Announces Financial Results for the Second Quarter of 2014
Marketwire - Tue Aug 12, 7:01AM CDT
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced financial results for its second quarter ended June 30, 2014.
ICCC: 4.59 (-0.38)
ImmuCell Initiates Pivotal Effectiveness Study to Prevent Calf Scours Caused by Rotavirus
Marketwire - Tue Jul 15, 7:02AM CDT
ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced today that it has commenced a pivotal effectiveness study designed to test antibodies derived from colostrum utilizing its proprietary technology against a bovine rotavirus challenge. The enrollment of calves for the pivotal effectiveness study is expected to be complete by the end of 2014, making product approval possible in 2015.
ICCC: 4.59 (-0.38)
ImmuCell Commences Manufacture of Nisin Necessary for Approval of Mast Out(R)
Marketwire - Wed Jul 09, 7:01AM CDT
ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced today that it has completed modifications to its manufacturing facility to produce pharmaceutical-grade Nisin, the active ingredient in its Mast Out(R) product, to address subclinical mastitis in lactating dairy cows.
ICCC: 4.59 (-0.38)
ImmuCell elects Paul R Wainman to board
M2 - Fri Mar 21, 5:53AM CDT
US-based animal health company ImmuCell (NASDAQ:ICCC) revealed on Thursday the addition of Paul R Wainman to its board of directors
ICCC: 4.59 (-0.38)
Paul R. Wainman Joins Board of Directors of ImmuCell Corporation
Marketwire - Thu Mar 20, 7:01AM CDT
ImmuCell Corporation (NASDAQ: ICCC) today announced that Mr. Paul R. Wainman has been appointed to its Board of Directors effective March 31, 2014.
ICCC: 4.59 (-0.38)
ImmuCell Announces Increase in Product Sales and Other Annual Financial Results
Marketwire - Thu Feb 13, 7:00AM CST
ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and twelve-month periods ended December 31, 2013.
ICCC: 4.59 (-0.38)
OTC Daily Alert Stock Watch - ImmuCell Corporation (NASDAQ: ICCC)
WorldStockWire - Wed Sep 11, 9:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ICCC: 4.59 (-0.38)
ImmuCell Corporation achieves 16% rise in product sales, with continued profitability
M2 - Tue Aug 13, 10:21AM CDT
Animal health company ImmuCell Corporation (NASDAQ:ICCC) on Monday reported a net income of USD6,000, or less than USD0.01 per share, for the three-month period ended 30 June 2013.
ICCC: 4.59 (-0.38)
ImmuCell Announces Increase in Product Sales and Continued Profitability
Marketwire - Mon Aug 12, 7:00AM CDT
ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and six-month periods ended June 30, 2013.
ICCC: 4.59 (-0.38)
Nasdaq stocks posting largest volume increases
AP - Thu Jul 18, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
JAKK: 6.51 (-0.03), ICCC: 4.59 (-0.38), ISIG: 2.98 (+0.03), KFFB: 8.13 (unch), CZFC: 12.00 (-0.49), GLDC: 4.40 (-0.01)
ImmuCell Suspends Mast Out(R) Partnering Effort; Pursuit of FDA Product Approval to Continue
Marketwire - Thu Jul 18, 7:01AM CDT
ImmuCell Corporation (NASDAQ: ICCC) today announced that it has suspended its active pursuit of a partner for Mast Out(R), its Nisin-based intramammary mastitis treatment product under development for dairy cows.
ICCC: 4.59 (-0.38)
First Defense(R) Is Now OMRI Listed and May Be Used With Certified Organic Dairy and Beef Cattle
Marketwire - Thu Jul 11, 7:00AM CDT
ImmuCell Corporation (NASDAQ: ICCC) today announced that First Defense(R), a USDA-approved scours preventative for newborn dairy and beef calves, has been reviewed by the Organic Materials Review Institute (OMRI) and has been listed with products eligible for use in certified organic production, subject to approval by USDA accredited certifiers.
ICCC: 4.59 (-0.38)
ImmuCell Announces Product Sales Increases and Other Financial Results
Marketwire - Thu Feb 14, 7:01AM CST
ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and twelve-month periods ended December 31, 2012.
ICCC: 4.59 (-0.38)
